Kari L. Kendra MD

Oncology•Columbus, OH

Associate Professor, Internal Medicine, Ohio State University College of Medicine

Join to View Full Profile

2050 Kenny RdTower 4th FloorColumbus, OH 43221
Phone+1 614-293-4320
Fax+1 614-293-2584

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1993 - 1998
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1990 - 1993
Rush Medical College of Rush University Medical CenterClass of 1990

Certifications & Licensure

OH State Medical License 2001 - 2026
NY State Medical License 1998 - 2002
WI State Medical License 1991 - 2001
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer Start of enrollment: 2005 Feb 25
Completed
Phase 2
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Start of enrollment: 2012 Nov 09
Completed
Phase 1
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01
Terminated
Phase 1, Phase 2
Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2014 Aug 22
Completed
Phase 1
Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19
ACTIVE_NOT_RECRUITING
PHASE2
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery Start of enrollment: 2017 Feb 06
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade.
Colin D Angell, Steven H Sun, Gabriella Lapurga, Brooke Benner, Dionisia Quiroga
Melanoma Research. 2025-04-01
The Association of the Microbiome with Melanoma Tumor Response to Immune Checkpoint Inhibitor Treatment and Immune-Related Adverse Events (NCT05102773).
Caroline Dravillas, Nyelia Williams, Marium Husain, Rebecca Hoyd, Ahmed Hussein
Medrxiv. 2025-01-31
Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.
Emily Schwarz, Brooke Benner, Robert Wesolowski, Dionisia Quiroga, Logan Good
JCI Insight. 2024-11-08

Journal Articles

Prognostic Gene Expression Profiling in Cutaneous Melanoma
Douglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology

Authored Content

Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020

Press Mentions

AACR Annual Meeting 2023: Therapy Advances for Patients with Rare Melanoma TypesMay 18th, 2023
Desmoplastic Melanoma Patients Respond "Exceptionally" Well to Treatment with Immunotherapy AloneMay 5th, 2023
Rare Melanoma Very Likely to Respond to Treatment with PembrolizumabMay 5th, 2023
Join now to see all